Abstract
Purpose :
Postoperative hypotony following PRESERFLO® MicroShunt implantation is a frequent cause of complications such as choroidal detachment and hypotony maculopathy. This study aims at evaluating the impact of intraluminal stenting of the PRESERFLO® during the early postoperative period.
Methods :
We retrospectively analyzed the data of 71 patients who underwent PRESERFLO® MicroShunt implantation with intraoperative placement of a Nylon 10-0 suture as intraluminal stent (PS) and compared the outcomes to those of an existing database of the traditional MicroShunt implantation technique (PT, n = 121). The primary outcome measure was the intraocular pressure (IOP) at one week postoperatively. Secondary, adverse hypotony, defined as IOP < 6mmHg with choroidal detachment and/or hypotony maculopathy were also assessed. Additionally, the time to stent removal and the IOP one week after stent removal were reported.
Results :
Preoperative IOP was 26.8 ±8.4 mmHg in PS and 26.5 ±8.4 mmHg in PT, respectively (p = 0.69). One week after surgery, the IOP dropped to 11.1 ±4.0 mmHg in PS and 7.9 ±3.5 in PT (p < 0.01). At one month, the IOP was 12.4 ±4.6 mmHg in PS and 10.8±5.3 mmHg in PT, respectively (p < 0.01). After 3 months, both groups showed similar IOP levels of 11.2 ±3.8 mmHg and 11.1 ±4.0 mmHg in PS and PT, respectively (p = 0.82). The presence of hypotony was significantly lower in PS compared to PT (8.5% vs 19.8 %, p < 0.05). In PS, the stent was removed after a median of 30.2 ±16.0 days. One week after stent removal, the IOP drop was 6.6 mmHg (16.6 ±3.8 to 10.0 ±4.4 mmHg, p < 0.01).
Conclusions :
Intraluminal stenting of the PRESERFLO® MicroShunt appears to be safe and effective in preventing adverse hypotony after MicroShuntimplantation in the early postoperative phase. However, some cases of hypotony were still observed after stenting, which remains to be explained.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.